Next 10 |
2024-05-01 22:06:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-04-30 17:45:11 ET Image source: The Motley Fool. Harmony Biosciences (NASDAQ: HRMY) Q1 2024 Earnings Call Apr 30, 2024 , 8:30 a.m. ET Operator Continue reading For further details see: Harmony Biosciences (HRMY) Q1 2024 Earnings Call Tran...
2024-04-30 16:00:00 ET Summary Harmony Biosciences Holdings, Inc. stock price fell sharply in October last year, as the lead drug pitolisant - approved to treat narcolepsy - missed endpoints in a late stage IH study. The company's Q3 2023 earnings saw Wakix revenues up 37% YoY and...
2024-04-30 13:49:15 ET Harmony Biosciences Holdings, Inc (HRMY) Q1 2024 Earnings Conference Call April 30, 2024 08:30 AM ET Company Participants Luis Sanay - Head of Investor Relations Jeffrey Dayno - President & Chief Executive Officer Jeffrey Dierks - Chief...
2024-04-30 10:01:07 ET More on Health Care Select Sector SPDR XLV: Pivotal Week Of Earnings For Healthcare Stocks XLV: Fundamentals Don't Support Overweighting Health Care XLV: Low-Cost Exposure To A Defensive Sector, While Achieving Strong Performance 19 out...
2024-04-30 08:53:48 ET More on Harmony Biosciences Harmony Biosciences Holdings, Inc. (HRMY) Q4 2023 Earnings Call Transcript Harmony Biosciences Non-GAAP EPS of $0.88 beats by $0.10, revenue of $154.6M misses by $0.19M Harmony Biosciences Q1 2024 Earnings Preview ...
2024-04-30 07:14:12 ET More on Harmony Biosciences Harmony Biosciences Holdings, Inc. (HRMY) Q4 2023 Earnings Call Transcript Harmony Biosciences Q1 2024 Earnings Preview Harmony inks licensing deal for sleep disorder therapy Seeking Alpha’s Quant Rati...
WAKIX ® (pitolisant) Net Revenue of $154.6 Million for First Quarter 2024; ~30% Growth Year-over-Year Supplemental New Drug Application for Pitolisant in Idiopathic Hypersomnia Planned for Second Half 2024 On Track Toward Pediatric Exclusivity to Extend WAKIX Exclusivit...
LPL Financial Holdings Inc. (LPLA) is expected to report $3.77 for Q1 2024 Banco Santander Brasil SA American Depositary Shares each representing one unit (BSBR) is expected to report $0.14 for Q1 2023 EnLink Midstream LLC representing Limited Partner Interests (ENLC) is expected to repor...
Harmony Biosciences Acquires Epygenix Therapeutics, Inc., Adding Late-Stage Epilepsy Franchise to Growing Pipeline of Innovative CNS Assets PR Newswire Lead Candidate, EPX-100, Holds Orphan Drug and Rare Pediatric Disease Designations EPX-100 in Pivotal Registrational ...
News, Short Squeeze, Breakout and More Instantly...
Harmony Biosciences Holdings Inc. Company Name:
HRMY Stock Symbol:
NASDAQ Market:
Growth stocks are attractive to many investors, as above-average financial growth helps these stocks easily grab the market's attention and pro...
2024-05-01 22:06:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-04-30 17:45:11 ET Image source: The Motley Fool. Harmony Biosciences (NASDAQ: HRMY) Q1 2024 Earnings Call Apr 30, 2024 , 8:30 a.m. ET Operator Continue reading For further details see: Harmony Biosciences (HRMY) Q1 2024 Earnings Call Tran...